These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 22082359)

  • 1. Fibrodysplasia ossificans progressiva: a blueprint for metamorphosis.
    Kaplan FS; Lounev VY; Wang H; Pignolo RJ; Shore EM
    Ann N Y Acad Sci; 2011 Nov; 1237():5-10. PubMed ID: 22082359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrodysplasia ossificans progressiva: diagnosis, management, and therapeutic horizons.
    Pignolo RJ; Shore EM; Kaplan FS
    Pediatr Endocrinol Rev; 2013 Jun; 10 Suppl 2(0 2):437-48. PubMed ID: 23858627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alk2 regulates early chondrogenic fate in fibrodysplasia ossificans progressiva heterotopic endochondral ossification.
    Culbert AL; Chakkalakal SA; Theosmy EG; Brennan TA; Kaplan FS; Shore EM
    Stem Cells; 2014 May; 32(5):1289-300. PubMed ID: 24449086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ACVR1 R206H mutation found in fibrodysplasia ossificans progressiva increases human induced pluripotent stem cell-derived endothelial cell formation and collagen production through BMP-mediated SMAD1/5/8 signaling.
    Barruet E; Morales BM; Lwin W; White MP; Theodoris CV; Kim H; Urrutia A; Wong SA; Srivastava D; Hsiao EC
    Stem Cell Res Ther; 2016 Aug; 7(1):115. PubMed ID: 27530160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibrodysplasia ossificans progressiva.
    Kaplan FS; Le Merrer M; Glaser DL; Pignolo RJ; Goldsby RE; Kitterman JA; Groppe J; Shore EM
    Best Pract Res Clin Rheumatol; 2008 Mar; 22(1):191-205. PubMed ID: 18328989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Granting immunity to FOP and catching heterotopic ossification in the Act.
    Kaplan FS; Pignolo RJ; Shore EM
    Semin Cell Dev Biol; 2016 Jan; 49():30-6. PubMed ID: 26706149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrodysplasia ossificans progressiva (FOP): A disorder of osteochondrogenesis.
    Kaplan FS; Al Mukaddam M; Stanley A; Towler OW; Shore EM
    Bone; 2020 Nov; 140():115539. PubMed ID: 32730934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The obligatory role of Activin A in the formation of heterotopic bone in Fibrodysplasia Ossificans Progressiva.
    Alessi Wolken DM; Idone V; Hatsell SJ; Yu PB; Economides AN
    Bone; 2018 Apr; 109():210-217. PubMed ID: 28629737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrodysplasia ossificans progressiva: mechanisms and models of skeletal metamorphosis.
    Kaplan FS; Chakkalakal SA; Shore EM
    Dis Model Mech; 2012 Nov; 5(6):756-62. PubMed ID: 23115204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1.
    Kaplan FS; Xu M; Seemann P; Connor JM; Glaser DL; Carroll L; Delai P; Fastnacht-Urban E; Forman SJ; Gillessen-Kaesbach G; Hoover-Fong J; Köster B; Pauli RM; Reardon W; Zaidi SA; Zasloff M; Morhart R; Mundlos S; Groppe J; Shore EM
    Hum Mutat; 2009 Mar; 30(3):379-90. PubMed ID: 19085907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation.
    van Dinther M; Visser N; de Gorter DJ; Doorn J; Goumans MJ; de Boer J; ten Dijke P
    J Bone Miner Res; 2010 Jun; 25(6):1208-15. PubMed ID: 19929436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigations of activated ACVR1/ALK2, a bone morphogenetic protein type I receptor, that causes fibrodysplasia ossificans progressiva.
    Kaplan FS; Seemann P; Haupt J; Xu M; Lounev VY; Mullins M; Shore EM
    Methods Enzymol; 2010; 484():357-73. PubMed ID: 21036241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. International physician survey on management of FOP: a modified Delphi study.
    Di Rocco M; Baujat G; Bertamino M; Brown M; De Cunto CL; Delai PLR; Eekhoff EMW; Haga N; Hsiao E; Keen R; Morhart R; Pignolo RJ; Kaplan FS
    Orphanet J Rare Dis; 2017 Jun; 12(1):110. PubMed ID: 28606101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of altered signal transduction in heterotopic ossification and fibrodysplasia ossificans progressiva.
    Shore EM; Kaplan FS
    Curr Osteoporos Rep; 2011 Jun; 9(2):83-8. PubMed ID: 21340697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An ACVR1
    Kaplan FS; Groppe JC; Xu M; Towler OW; Grunvald E; Kalunian K; Kallish S; Al Mukaddam M; Pignolo RJ; Shore EM
    Am J Med Genet A; 2022 Mar; 188(3):806-817. PubMed ID: 34854557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Depletion of Mast Cells and Macrophages Impairs Heterotopic Ossification in an Acvr1
    Convente MR; Chakkalakal SA; Yang E; Caron RJ; Zhang D; Kambayashi T; Kaplan FS; Shore EM
    J Bone Miner Res; 2018 Feb; 33(2):269-282. PubMed ID: 28986986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BMP signaling and skeletal development in fibrodysplasia ossificans progressiva (FOP).
    Towler OW; Shore EM
    Dev Dyn; 2022 Jan; 251(1):164-177. PubMed ID: 34133058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An anti-ACVR1 antibody exacerbates heterotopic ossification by fibro-adipogenic progenitors in fibrodysplasia ossificans progressiva mice.
    Lees-Shepard JB; Stoessel SJ; Chandler JT; Bouchard K; Bento P; Apuzzo LN; Devarakonda PM; Hunter JW; Goldhamer DJ
    J Clin Invest; 2022 Jun; 132(12):. PubMed ID: 35503416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrodysplasia ossificans progressiva: middle-age onset of heterotopic ossification from a unique missense mutation (c.974G>C, p.G325A) in ACVR1.
    Whyte MP; Wenkert D; Demertzis JL; DiCarlo EF; Westenberg E; Mumm S
    J Bone Miner Res; 2012 Mar; 27(3):729-37. PubMed ID: 22131272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice With the Human ACVR1(R206H) Fibrodysplasia Ossificans Progressiva (FOP) Mutation.
    Chakkalakal SA; Uchibe K; Convente MR; Zhang D; Economides AN; Kaplan FS; Pacifici M; Iwamoto M; Shore EM
    J Bone Miner Res; 2016 Sep; 31(9):1666-75. PubMed ID: 26896819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.